Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in ...

Mikela Pettigrew, B.S.N., RN, OCN,, exemplifies extraordinary compassion and dedication. Every day, she fulfills a promise ...

Five scientists from The University of Texas MD Anderson Cancer Center will be recognized with Scientific Achievement Awards ...

uGDB, utilizing next-generation sequencing to detect bladder cancer-associated mutations and DNA alterations, has previously shown associations with recurrence and therapy response.

Monitoring and analyzing gut microbes may help predict how myeloma patients will respond to CAR T-cell therapy, research ...

Surgery may not be the best next course of treatment for patients with early-stage breast cancer who had a complete response to neoadjuvant (pre-surgical) chemotherapy and standard radiation treatment ...

He serves as director of Translational Research Career Development, coordinating MD Anderson’s physician-scientist and K12 clinician-investigator training programs. Of the 45 graduates of the ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

A gut toxin that’s been linked to colorectal cancers for more than two decades may be contributing to the sharp rise of the ...

Chronic lymphocytic leukemia (CLL) cell–derived exosomes demonstrated the ability to alter healthy donor cell function and ...

Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a ...